News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
FDA Questions Genzyme Corporation Knee Pain Treatment Study
December 5, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, Dec 5 (Reuters) - A study of Genzyme Corp's latest version of its injectable knee pain treatment may not be strong enough to support the therapy, U.S. regulatory reviewers said in an analysis released on Friday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
MORE ON THIS TOPIC
Insights
Swiss CDMOs and CROs ride a new wave of growth amid surge in global demand
October 5, 2026
·
6 min read
·
Jennifer C. Smith-Parker
Duchenne muscular dystrophy
Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027
October 2, 2026
·
3 min read
·
Heather McKenzie
Women’s health
Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS
October 2, 2026
·
2 min read
·
Tristan Manalac
Drug Development
Merck’s antibody impresses with ‘highly competitive’ data in chronic skin disease
October 1, 2026
·
2 min read
·
Tristan Manalac
